| 000 | 01604 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250518034641.0 | ||
| 264 | 0 | _c20191118 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a1179-190X | ||
| 024 | 7 |
_a10.1007/s40259-019-00352-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWu, Xiaoyun | |
| 245 | 0 | 0 |
_aA Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin _h[electronic resource] |
| 260 |
_bBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy _cJun 2019 |
||
| 300 |
_a335-342 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBevacizumab _xpharmacokinetics |
| 650 | 0 | 4 |
_aBiosimilar Pharmaceuticals _xpharmacokinetics |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfusions, Intravenous _xmethods |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPlasma _xmetabolism |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aWynne, Chris | |
| 700 | 1 | _aXu, Chenchao | |
| 700 | 1 | _aGan, Yiting | |
| 700 | 1 | _aWang, Chaohe | |
| 700 | 1 | _aThomas, Bert E | |
| 700 | 1 | _aYu, Jin-Chen | |
| 700 | 1 | _aLi, Shengfeng | |
| 700 | 1 | _aZhang, Li | |
| 773 | 0 |
_tBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy _gvol. 33 _gno. 3 _gp. 335-342 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40259-019-00352-7 _zAvailable from publisher's website |
| 999 |
_c29619515 _d29619515 |
||